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ABSTRACT
Background: The Medicaid population experienced an elevated risk of opioid overdose death. Higher
risks of a health condition or worse health outcomes could mean high costs imposed on public sources
of insurance. In this study, we compared the length of stay and total charge of hospitalized opioid
overdose patients across insurance types to shed light on the financial burden of opioid epidemic across
different types of payers. Method: Our sample includes all opioid overdose hospitalizations in the
2012–2013 South Carolina Patient Encounter database. Length of stay and total hospital charge are
the two dependent variables. The key independent variable is the insurance status, categorized as: self-
pay, commercial insurance, Medicare, Medicaid, and other payers (other government plan and charitable
plans). Multilevel models were applied to account for the clustering effect of each hospital. The patients’
age, gender, race/ethnicity, and Charlson Comorbidity Index were used as covariates. Results: A total of
1,262 hospitalizations were included. Medicaid patients stayed longer in hospital (β = 1.815, 95%
confidence interval = [0.406–3.224]) and had higher total charge (β = $6,695.2, 95% CI = [215.1–13,175.3)
compared with patients with commercial insurance. Conclusion: Medicaid patients’ longer hospitaliza-
tion and higher hospital charge suggest disparity at the hospital treatment stage.
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Background
Certain parts of the United States (U.S.) and Canada have
seen an unprecedented increase in morbidity and mortality
associated with use of opioid in recent years (Kolodny et al.,
2015; Morin, Eibl, Franklyn, & Marsh, 2017), and the rise in
opioid overdose deaths have also been noted in countries such
as Australia and the United Kingdom (Dhalla, Persaud, &
Juurlink, 2011). In the U.S., counties with higher Medicaid
enrolment rates and higher unemployment rates had more
opioids prescribed (Guy et al., 2017) and those with Medicaid
or without insurance (Becker et al., 2008) were more likely to
have opioid use disorder (OUD). While risk factors of OUD
incidence have been identified by previous literature (Edlund,
Steffick, Hudson, Harris, & Sullivan, 2007; Turk, Swanson, &
Gatchel, 2008), few studies have further examined whether the
costs of opioid overdose hospitalizations are disproportionally
distributed across different payers due to different underlying
reasons.
There have been reports about the rise of prescription
opioids among the Medicaid population (Desai, Hernandez-
Diaz, Bateman, & Huybrechts, 2014) and the Medicaid popu-
lation experienced an elevated risk of opioid overdose death
(“Overdose Deaths Involving Prescription Opioids Among
Medicaid Enrollees – Washington, 2004–2007,” 2009).
Recent evidence suggests that for the same procedure of
total hip replacement Medicaid patients faced significantly
worse outcomes than those with private insurance,
a phenomenon that could reflect broader disparities in the
health-care system (Xu et al., 2017). Higher risks of a health
condition or worse health outcomes could mean high costs
imposed on public sources of insurance. In this study, we
compared the length of stay and total charge of hospitalized
opioid overdose patients across insurance types to shed light
on the financial burden of opioid epidemic across different
types of payers.
Methods
Our analytical dataset for opioid overdose hospitalizations
was constructed from the 2012–2013 South Carolina Patient
Encounter database – the “universe” of all hospitalizations at
non-federal health-care providers in the state of South
Carolina (Feng, Nietert, & Adams, 2009). This database can
be used for multiple purposes including identifying risk fac-
tors of hospital outcomes among the state’s inpatients of
a defined disease (L. Shi, Zhang, Chen, & Truong, 2016).
Using the inpatient component of this database, hospitaliza-
tions with ICD 9 codes 965.00, 965.01, 965.02, and 965.09 (Y.
Shi, 2017) in their primary diagnoses at admission were iden-
tified to construct our analytical sample.
Two outcome variables were examined in this study: length
of stay (number of days of the hospitalization) and total
charge (dollars). Because of the nature of these two outcome
variables, we had to further limit our analytical sample. Those
with discharge status as “expired” or “hospice” were excluded
because death or “discharged to hospice” event truncated the
hospitalization, confounding the association between insur-
ance status and the two outcome variables.
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The key independent variable is the insurance status, cate-
gorized as: self-pay, commercial insurance, Medicare,
Medicaid, and other payers (including indigent/charitable
organization and other government payers). “Other payers”
is a category that includes state and local governments’ health
plans and charitable funds hospitals could have to pay for
certain hospitalizations. The payer in this category of “other
payer” is therefore public or nonprofit.
Multilevel models were applied to account for the grouping
structure of data – patients are nested within hospitals. The
patients’ age, gender, race/ethnicity, and Charlson
Comorbidity Index (CCI)(Charlson, Szatrowski, Peterson, &
Gold, 1994; Stagg, 2017) – computed from the secondary
diagnoses of the hospitalization were used as the control
variables at the individual level. Race/ethnicity was recoded
as 1 for non-Hispanic Whites and 0 for other racial/ethnic
groups as there were small counts of minority races in our
sample.
STATA 14.0’s function “mixed” was used to contain both
fixed effects and random-intercept effects for our multilevel
linear regressions (Rabe-Hesketh, Skrondal, & Pickles, 2002;
StataCorp, 2013), with hospital ID set as the cluster variable.
Results
A total of 1,262 hospitalizations clustered within 55 hospitals
were included in our multilevel analyses. Table 1 presents the
descriptive statistics of variables used in our multilevel analyses
by insurance statuses. ANOVA analyses show that total hospi-
tal charge was significantly different across insurance statuses
(p = .001). Statistically significant differences across insurance
statuses were also observed for length of stay (p = .002), CCI
(p < .001), and age (p < .001). Medicaid patients had notably
the highest average length of stay while total hospital charge
was highest among the “other payer” group.
Table 2 presents the results of our multilevel analyses. Both
multilevel models are significantly different from single-level
models based upon the likelihood ratio tests, signaling that the
cluster effect at the hospital level is significant. Among the
nonfatal opioid overdose hospitalizations, Medicaid-covered
patients had longer stay in the hospital (β = 1.815, 95%
confidence interval = [0.406–3.224]) and larger amounts of
total charge (β = $6,695.2, 95% confidence interval = [215.1–-
13,175.3) compared with patients who had commercial insur-
ance, after controlling for age, gender, race/ethnicity, and
CCI. These results mean that on average opioid overdose
inpatients with Medicaid as the primary payer stayed 1.815
days longer in the hospital and incurred an excess of $6,692.2
in total hospital charge as compared with opioid overdose
inpatients with commercial insurance (the reference group
in our statistical model). Meanwhile, opioid overdose inpati-
ents with Medicare or those self-pay patients had no statisti-
cally significant difference from those inpatients with
commercial insurance in terms of length of stay and total
hospital charge.
Patients with “other payers” (other government plans,
charitable/indigent care) had an excess of $7,814.6 (95% con-
fidence interval = [448.4–15,180.9) as compared with those
with commercial insurance. Length of stay for those patients
of “other payers” is not statistically significant as compared to
private insurance, though the coefficient had the positive sign
(consistent with the pattern of total hospital charge).
Discussion
Our data analyses confirm the important role Medicaid plays
in reimbursing for opioid poisoning hospitalizations: 43% of
the opioid overdose hospitalizations in our sample had
Medicaid as the primary payer, a percentage by far larger
than the percentage of Medicaid enrollees in the South
Carolina population (25%) (The Center for Medicaid and
CHIP Services, 2016). This reflects the excess burden of the
opioid epidemic on Medicaid financing as well as illustrates
the potential role Medicaid has in controlling the opioid
epidemic (Sharp et al., 2018). Similar interpretation can be
drawn for the “other payers,” which consisted of a large
proportion of public funding as explained earlier.
Health disparity occurs at different stages of the natural
history of an OUD: the geographic disparity is salient for the
OUD incidence and opioid overdose risk (Dunn et al., 2016;
Keyes, Cerdá, Brady, Havens, & Galea, 2014) whereas the
racial and gender disparities are significant at the treatment
Table 1. Descriptive statistics of the sample with nonfatal opioid overdose hospitalizations in South Carolina 2012–2013.
Payer status
variables
Commercial
insurance Self-pay Medicare Medicaid
Other
payers1
Bivariate associations with payer
status
Continuous variables (mean and standard
deviation)
p value from ANOVA tests
Age (years) 43.67 36.07 61.12 41.91 42.22 <0.001
(15.95) (11.99) (12.85) (14.98) (15.11)
Charlson Comorbidity Index 0.62 0.25 1.30 0.85 0.54 <0.001
(1.36) (0.75) (1.54) (1.33) (1.04)
Length of stay (days) 3.40 3.48 4.31 5.32 4.50 0.002
(3.88) (4.49) (4.23) (14.18) (5.37)
Total hospital charge ($) 24,505.97 25,213.48 33,184.40 31,829.69 33,343.57 0.001
(23,888.72) (25,581.98) (31,528.02) (40,605.66) (38,140.90)
Categorical variables (frequency/column percent) p-value from Chi-square tests
Female 93 102 323 126 60 <0.001
57.41% 40.16% 59.81% 66.32% 51.72%
Non-Hispanic White 150 228 470 163 99 0.193
92.59% 89.76% 87.04% 85.79% 85.34% Total
Sample size 162 254 540 190 116 1,262
Note:
1. “Other payers” include state government insurance plan for public employees and hospital funds for indigent patients.
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stage (Hadland et al., 2017). Our findings that patients with
Medicaid stayed longer in hospital and had higher charge
suggests there could be disparity at the treatment stage during
the hospitalization. It could be that these patients had delayed
treatment, resulting in more complication to treat. While we
already know that Medicaid enrollees might be at elevated risk
for receiving opioid prescriptions as compared with the non-
Medicaid population (Ailes et al., 2015), there has been little
information about the severity difference between Medicaid
patients and other patients at the time of an opioid overdose
hospitalization. The fact that the 43% of the opioid overdose
hospitalizations were Medicaid patients and the Medicaid
OUD patients faced substantially higher charge and longer
stay in the hospital warrants attention from federal and state
stakeholders of Medicaid, either from an overdose prevention
perspective or from a perspective of cost control. While all
payers might have an incentive to minimize opioid overdose
among their beneficiaries, Medicaid administrators could find
it particularly efficient to prevent opioid overdose among its
enrollees, since the cost of their hospitalizations is notably
higher than those with commercial insurance. In other words,
a more “proactive approach” in overdose prevention could
potentially save costs.
The relatively low reimbursement rate of Medicaid as
compared with commercial insurance could create incentives
among health-care providers to discriminate against Medicaid
patients (Meyer, 2001) and this kind of possible discrimina-
tion could in the long run result in worse outcomes and
longer duration of hospitalization among Medicaid patients
(Smoyer Tomic, Wilson, Smith, & Agodoa, 2013). In a 2013
study of inpatients with systematic heart failure where
researchers identified longer length of stay and higher mor-
tality rate among Medicaid patients than those with private
insurance, the latter were found to be more likely to receive
inpatient procedures (Smoyer Tomic et al., 2013). This possi-
ble mechanism could have resulted in the worse CCI and
longer hospitalization among Medicaid patients as we see in
this study.
It has been well documented that Medicaid patients were
more limited by their access to rehabilitation facilities than
those with commercial insurance: (i) fewer providers accept
Medicaid patients; and (ii) for those Medicaid patients getting
service, they waited significantly longer that those with private
insurance (Rogers, Penvose, Curry, DeGiacomo, & Li, 2018).
This longer delay before admission to rehabilitation might
have also contributed to higher severity among Medicaid
patients with OUD and subsequently led to longer stay at
the hospital and higher total expenditure. While our current
study cannot examine these hypothetical mechanisms,
Medicaid decision makers and public health stakeholders
might find it optimal to close these gaps in OUD treatment,
especially if follow-up studies clarify the causal pathways
behind the higher hospitalization costs and longer stays of
Medicaid opioid overdose patients.
South Carolina faces elevated risk for OUD in that its
4.89 million residents in 2015 filled nearly 4.5 million opioid
prescriptions, a rate greater than 1.5 times the national aver-
age (Arnold, Arshonsky, Bloch, Holzman, & Sade, 2019). Our
analytical sample included only the inpatient data, therefore
presenting only a portion of the health-care expenditure attri-
butable to OUD. In 2015, South Carolina had 105.8 opioid-
related emergency department visits per 100,000 population,
representing a 50.3% increase since 2009 (Weiss et al., 2017).
Further studies can look at the distribution of reimbursement
for ED visits across types of payers.
Our dataset is limited in that it does not include specific
clinical information such as laboratory results for the
admitted OUD patients and thus we do not know the specific
severity of overdose in each insurance category, which could
be a confounder in the association between payer status and
hospitalization outcomes. We tried to compensate that by
computing a CCI from the secondary diagnoses of the hospi-
tal discharge data. However, the index alone might not cap-
ture all the possible severity differences between Medicaid
patients and commercial insurance patients. Another limita-
tion is our data are limited to two years 2012 and 2013, which
does not capture the latest changes of the opioid epidemic in
the state of South Carolina (e.g., changes in the type of opioid
substance used by the patients, which might influence the
mortality, morbidity and the expenditure outcomes). Finally,
there are significant state-level differences in Medicaid cover-
age for treatment of substance use disorder including OUD
treatment (Grogan et al., 2016) and each state’s legislative
environment for private insurance plans’ coverage for OUD
could also vary. Therefore, findings from one state cannot be
easily generalized to other states. For follow-up studies, we
look forward to addressing these limits by using more
Table 2. Multilevel Linear Regressions of outcomes by payer status, nonfatal
opioid overdose hospitalizations in South Carolina 2012–2013.
Length of stay
(days)
Total
hospital charge ($)
Regression coefficient
[95% Confidence
Interval]
Regression coefficient
[95% Confidence
Interval]
Non-Hispanic Whites1 0.296 −1,286.2
[−0.864,1.456] [−6,666.9,4,094.6]
Age 0.0172 129.8*
[−0.011,0.0448] [2.574,257.0]
Payer (commercial insurance as the reference group)
Self-pay 0.358 1789.0
[−0.982,1.698] [−4,371.9,7,949.9]
Medicare 0.484 4,514.3
[−0.789,1.757] [−1,331.6,10,360.2]
Medicaid 1.815* 6,695.2*
[0.406,3.224] [215.1,13175.3]
Other payers 1.035 7,814.6*
[−0.565,2.636] [448.4,15,180.9]
Female −0.233 −1311.5
[−0.987,0.522] [−4,780.0,2,156.9]
Charlson Comorbidity index 0.120 1,051.7
[−0.183,0.423] [−339.3,2,442.7]
N 1,262 1,262
Notes:
1. Non-Whites and Hispanics are set as the reference group.
2. 95% confidence intervals in brackets
3. * p < 0.05, ** p < 0.01, *** p < 0.001
4. Natural log of standard deviations of the hospital-level random effects are
significant for both models: Length of stay (1.893, 95% Confidence Interval:
[1.854, 1.932]), total charge: (10.32, 95% Confidence Interval: [10.28, 10.36]).
5. Natural log of standard deviation of the individual-level errors is significant for
the model about total charge (8.863, 95% Confidence Interval: [8.516, 9.210])
but not for the model about the length of stay (−0.110, 95% Confidence
Interval: [−0.595, 0.376]).
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updated national data sources with longitudinal structure and
richer information about the patient’s OUD history.
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